Koselugo Europäische Union - Norwegisch - EMA (European Medicines Agency)

koselugo

astrazeneca ab - selumetinib sulfate - neurofibromatosis 1 - antineoplastiske midler - koselugo as monotherapy is indicated for the treatment of symptomatic, inoperable plexiform neurofibromas (pn) in paediatric patients with neurofibromatosis type 1 (nf1) aged 3 years and above.

Cometriq Europäische Union - Norwegisch - EMA (European Medicines Agency)

cometriq

ipsen pharma - cabozantinib - skjoldbrusk neoplasmer - antineoplastiske midler - behandling av voksne pasienter med progressiv, uoppløselig lokalt avansert eller metastatisk medulær skjoldbrusk-karsinom.

Raplixa Europäische Union - Norwegisch - EMA (European Medicines Agency)

raplixa

mallinckrodt pharmaceuticals ireland limited - human fibrinogen, human trombin - hemostase, kirurgisk - antihemoragika - støttende behandling der standard kirurgiske teknikker er utilstrekkelige for forbedring av hemostase. raplixa må brukes i kombinasjon med en godkjent gelatin svamp. raplixa er indisert hos voksne over 18 år.

Midazolam Accord 5 mg/ ml Norwegen - Norwegisch - Statens legemiddelverk

midazolam accord 5 mg/ ml

accord healthcare b.v. - midazolamhydroklorid - injeksjons-/infusjonsvæske, oppløsning - 5 mg/ ml

Midazolam Accord 1 mg/ ml Norwegen - Norwegisch - Statens legemiddelverk

midazolam accord 1 mg/ ml

accord healthcare b.v. - midazolamhydroklorid - injeksjons-/infusjonsvæske, oppløsning - 1 mg/ ml

Vosevi Europäische Union - Norwegisch - EMA (European Medicines Agency)

vosevi

gilead sciences ireland uc - sofosbuvir, velpatasvir, voxilaprevi - hepatitt c, kronisk - antivirale midler til systemisk bruk - vosevi is indicated for the treatment of chronic hepatitis c virus (hcv) infection in patients aged 12 years and older and weighing at least 30 kg. (se kapittel 4. 2, 4. 4 og 5.

Recrea Forte 5 % w/v Norwegen - Norwegisch - Statens legemiddelverk

recrea forte 5 % w/v

viatris as - minoksidil - liniment, oppløsning - 5 % w/v

Selsun 25 mg/ ml Norwegen - Norwegisch - Statens legemiddelverk

selsun 25 mg/ ml

opella healthcare france sas - selendisulfid - sjampo - 25 mg/ ml

Trogarzo Europäische Union - Norwegisch - EMA (European Medicines Agency)

trogarzo

theratechnologies europe limited - ibalizumab - hiv-infeksjoner - antivirale midler til systemisk bruk - trogarzo, i kombinasjon med andre antiretroviral(s), er indisert for behandling av voksne infisert med multidrug resistent hiv-1-infeksjon for hvem det er ellers ikke mulig å konstruere en undertrykkende antiviralt regime.

Cabometyx Europäische Union - Norwegisch - EMA (European Medicines Agency)

cabometyx

ipsen pharma - cabozantinib (s)-malate - carcinoma, renal cell; carcinomas, hepatocellular - antineoplastiske midler - renal cell carcinoma (rcc)cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (rcc):in treatment-naïve adults with intermediate or poor risk,in adults following prior vascular endothelial growth factor (vegf)-targeted therapy. cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults. hepatocellular carcinoma (hcc)cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (hcc) in adults who have previously been treated with sorafenib.